Welcome to STN International! Enter x:x

LOGINID:sssptaul25txc

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | | |
|---|---|---|---|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | SEP 09 | CA/CAplus records now contain indexing from 1907 to the present |
| NEWS | 4 | AUG 05 | New pricing for EUROPATFULL and PCTFULL effective August 1, 2003 |
| NEWS | 5 | AUG 13 | Field Availability (/FA) field enhanced in BEILSTEIN |
| NEWS | 6 | AUG 18 | Data available for download as a PDF in RDISCLOSURE |
| NEWS | 7 | AUG 18 | Simultaneous left and right truncation added to PASCAL |
| NEWS | 8 | AUG 18 | FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation |
| NEWS | 9 | AUG 18 | Simultaneous left and right truncation added to ANABSTR |
| NEWS | 10 | SEP 22 | DIPPR file reloaded |
| NEWS | 11 | SEP 25 | INPADOC: Legal Status data to be reloaded |
| NEWS | 12 | SEP 29 | DISSABS now available on STN |
| NEWS | 13 | OCT 10 | PCTFULL: Two new display fields added |
| NEWS | 14 | OCT 21 | BIOSIS file reloaded and enhanced |

| | |
|---|---|
| NEWS EXPRESS | OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003 |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:52:44 ON 22 OCT 2003

=> file medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'ADISCTI' ENTERED AT 13:52:57 ON 22 OCT 2003

FILE 'ADISINSIGHT' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 13:52:57 ON 22 OCT 2003

FILE 'CAPLUS' ENTERED AT 13:52:57 ON 22 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'DISSABS' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBAL' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IPA' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 13:52:57 ON 22 OCT 2003

FILE 'NAPRALERT' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'NUTRACEUT' ENTERED AT 13:52:57 ON 22 OCT 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PASCAL' ENTERED AT 13:52:57 ON 22 OCT 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHARMAML' ENTERED AT 13:52:57 ON 22 OCT 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'SCISEARCH' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'TOXCENTER' ENTERED AT 13:52:57 ON 22 OCT 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 13:52:57 ON 22 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:52:57 ON 22 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s beta (3w) adrenoceptor?
L1 114639 BETA (3W) ADRENOCEPTOR?

=> s l1 and oesophagitis
L2 6 L1 AND OESOPHAGITIS

=> d l2 1-6 bib, ab, kwic

L2 ANSWER 1 OF 6 ADISCTI COPYRIGHT (C) 2003 Adis Data Information BV on STN
AN 2003:3391 ADISCTI
DN 800944184
TI A proton-pump ihibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux.
ADIS TITLE: Rabeprazole: therapeutic use.
Asthma
In patients with and without gastro-oesophageal reflux disease.
AU Tsugeno H; Mizuno M; Fujiki S; Okada H; Okamoto M; et al.
CS Okayama University Medical School, Okayama, Japan.
SO Scandinavian Journal of Gastroenterology (May 1, 2003), Vol. 38, pp. 456-461
DT Study
RE Obstructive Airways Disease| Peptic Ulcer Disease
FS Summary
LA English
WC 617
TX. . . the American Thoracic Society criteria; they were asymptomatic, stable and not experiencing exacerbations.
GORD was confirmed by endoscopic findings of reflux **oesophagitis** or by QUEST questionnaire scores >4.
Concomitant medication: inhaled beclomethasone 200-1000 microg/day; prednisolone; **beta** sub(2)-**adrenoceptor** agonists; leukotriene antagonists; xanthines; ranitidine

L2 ANSWER 2 OF 6 ADISCTI COPYRIGHT (C) 2003 Adis Data Information BV on STN
AN 1994:61561 ADISCTI
DN 800259415
TI Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina.
ADIS TITLE: Propranolol vs trimetazidine: therapeutic use.
Angina pectoris.
AU Detry J M; Sellier P; Pennaforte S; Cokkinos D; Trimetazidine European Multicenter Study Group.
CS Saint-Luc University Hospital, Brussels, Belgium.
SO British Journal of Clinical Pharmacology (Mar 1, 1994), Vol. 37, pp. 279-288
DT Study
RE Ischaemic Heart Disease
FS Summary
LA English
WC 551
SIDE. . .

| | | |
|---|---|---|
| Sleep disturbances | 5 | 2 |
| Muscular cramps | 1 | 5 |
| Cold extremities/Raynaud's phenomenon | 5 (1 withdrawn) | 1 |
| Effort-induced discomfort | 2 | 4 |
| Gastralgia/**oesophagitis** | 4 | 2 |
| Dyspnoea | 3 | 2 |
| Headache | 3 | 1 |
| Cutaneous signs | 3 | 1 |
| Sexual disturbances | 3 | 0 |
| Paraesthesia | 3 | 0 |

Bradycardia. . .
CT Drug Descriptors: Propranolol, therapeutic use; Adrenoceptor antagonists, therapeutic use; Antiarrhythmics, therapeutic use; Antihypertensives, therapeutic use; Antimigraines, therapeutic use; **Beta adrenoceptor** antagonists, therapeutic use; Cardiovascular therapies, therapeutic use; Class II antiarrhythmics, therapeutic use; Ischaemic heart disorder therapies, therapeutic use;

Neuropsychotherapeutics, therapeutic. . .

L2 ANSWER 3 OF 6 ADISCTI COPYRIGHT (C) 2003 Adis Data Information BV on STN
AN 1994:57698 ADISCTI
DN 800331943
TI Esophageal candidiasis as a complication of inhaled corticosteroids.
AU Houser W L; Simon M R; Smith K A.
SO 1994 Annual Meeting American College of Allergy and Immunology (Jan 1, 1994), pp. 36
DT Citation
RE Obstructive Airways Disease
FS Citation
LA English
CT Drug Descriptors: Pirbuterol, adverse reactions; Adrenoceptor agonists, adverse reactions; Antiasthmatics, adverse reactions; Antibronchitics, adverse reactions; **Beta** 2 **adrenoceptor** agonists, adverse reactions; **Beta adrenoceptor** agonists, adverse reactions; Bronchodilators, adverse reactions; Neurotransmitter agonists, adverse reactions; Sympathomimetics, adverse reactions; Triamcinolone, adverse reactions; Anti inflammatories, adverse reactions;. . . Disease Descriptors: Candidiasis, drug induced; Infections, drug induced; Mycoses, drug induced; Gastrointestinal disorders, drug induced; Digestive system disorders, drug induced; **Oesophagitis**, drug induced; Inflammation, drug induced; Oesophageal disorders, drug induced
CT Other Descriptors: Elderly

L2 ANSWER 4 OF 6 PHIN COPYRIGHT 2003 PJB on STN

AN 87:2017 PHIN
DN S00110198
DED 26 Feb 1987
TI Glaxo reveals R+D
SO Scrip (1987) No. 1184 p8
DT Newsletter
FS FULL
TX Sufotidine. . . . 24-hour control of acid secretion appears to be achievable and sufotidine may be superior to shorter-acting drugs, especially in reflux **oesophagitis**, the company believes. The first marketing applications may be filed in the second quarter of 1990.

TX GR 39069 is a selective **beta**(1)-**adrenoceptor** stimulant and an alpha(1)-adrenoceptor blocker. The company describes it as a cardiac stimulant which reduces peripheral resistance by dilating peripheral. . .

L2 ANSWER 5 OF 6 USPATFULL on STN
AN 1998:51774 USPATFULL
TI Heterocyclic ethanolamine derivatives with .beta.-adrenoreceptor agonistic activity
IN Beeley, Lee James, Dorking, United Kingdom
Dean, David Kenneth, Dorking, United Kingdom
PA SmithKline Beecham plc, Brentford, United Kingdom (non-U.S. corporation)
PI US 5750701 19980512
WO 9525104 19950921
AI US 1996-704699 19960916 (8)
WO 1995-EP794 19950303
19960916 PCT 371 date
19960916 PCT 102(e) date
PRAI GB 1994-5019 19940315
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Wong, King Lit

LREP Kinzig, Charles M., Lentz, Edward T.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein, X represents a moiety of formula (a), in which A.sup.1 represents --CH.dbd.CH.dbd., NH, S or O; A.sup.2 represents an oxo or a thioxo group; A.sup.3 represents H or an alkylcarbonyl group; and A.sup.4 represents hydroxy or NR.sup.s R.sup.t wherein R.sup.s and R.sup.t each independently represents H or alkyl; R.sup.0 and R.sup.1 each independently represents hydrogen or an alkyl group; R.sup.2 represents OCH.sub.2 CO.sub.2 H, or an ester or amide thereof, or R.sup.2 represents a moiety of formula (b), wherein R.sup.4 and R.sup.5 each independently represent hydrogen, alkyl, hydroxyalkyl, cycloalkyl or R.sup.4 together with R.sup.5 represents (CH.sub.2).sub.n wherein n is 2, 3 or 4; and R.sup.3 represents hydrogen, halogen, alkyl or alkoxy or R.sup.3 together with R.sup.2 represents a moiety of formula (c) or an ester or amide thereof, wherein R represents hydrogen, alkyl, hydroxymethyl or a moiety of formula (CH.sub.2).sub.n CO.sub.2 H, wherein n is zero or an integer 1, 2 or 3, or an ester or amide thereof; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound and composition in medicine.
SUMM These compounds are also indicated to have potential in the treatment of gastrointestinal disorders such as peptic ulceration, **oesophagitis**, gastritis and duodenitis, intestinal ulcerations, including inflammatory bowel disease, and irritable bowel syndrome and also for the treatment of gastrointestinal. . .
DETD Agonist Activity at Rat .beta..sub.1 and .**beta**..sub.2 **Adrenoceptors** In Vitro
DETD .**beta**..sub.1 -**Adrenoceptor** Agonism: Female Sprague-Dawley rats (150-250 g) are killed by a blow to the head and exsanguinated. Spontaneously beating right atria. . . from the tension signal using a Lectromed Type 4522 ratemeter. All traces are recorded on a Lectromed M4 chart recorder. .**beta**.-**adrenoceptor** agonists are then added to the Krebs medium in a cumulative fashion and the results expressed as a percentage increase. . .
DETD .**beta**..sub.2 -**Adrenoceptor** Agonism: Rat uterine horns are removed and bisected longitudinally. Each tissue is tied to a glass tissue holder and placed. . .
DETD .**beta**..sub.3 -**Adrenoceptor**-Mediated Adenylyl Cyclase Activity: Adenylyl cyclase activity was assayed by the method of Kirkham et. al..sup.2 by the addition of 40 .mu.l (70-80 .mu.g protein) to the incubation medium of the above CHO cell plasma membranes transfected with the human .**beta**..sub.3 -**adrenoceptor**. cAMP produced over 20 minutes was separated from ATP by the method of Salomon et al..sup.3. Agonist EC.sub.50 values and. . .

L2 ANSWER 6 OF 6 USPATFULL on STN
AN 1998:25219 USPATFULL
TI Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
IN Beeley, Lee James, Dorking, England
Thompson, Mervyn, Harlow, England
Dean, David Kenneth, Dorking, England
Kotecha, Nikesh Rasiklal, Welwyn Garden City, England
Berge, John Michael, Merstham, England
Ward, Robert William, Great Dunmow, England

PA SmithKline Beecham p.l.c., Brentford, England (non-U.S. corporation)
PI US 5726165 19980310
AI US 1995-465486 19950605 (8)
PRAI GB 1994-15304 19940729
GB 1994-23179 19941117
DT Utility
FS Granted
EXNAM Primary Examiner: Ambrose, Michael G.
LREP Simon, Soma G., Kinzig, Charles M., Lentz, Edward T.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2801
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula (I): ##STR1## or a pharmaceutically acceptable salt, or solvate thereof, wherein,

R.sup.o represents an aryl group, optionally substituted;

X represents O or S;

R.sup.1 and R.sup.1a each independently represents hydrogen or an alkyl group;

R.sup.2 represents OCH.sub.2 CO.sub.2 H, or an ester or amide thereof, or R.sup.2 represents a moiety of formula (b): ##STR2## wherein R.sup.4 represent hydrogen, alkyl, hydroxyalkyl, arylalkyl, aralkyloxyalkyl or cycloalkyl and R.sup.5 represent hydroxy, alkoxy, arylalkyloxy, hydroxyalkyloxy, alkoxyalkyloxy, arylalkoxyalkyloxy, cycloalkyloxy, hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, arylalkyl, arylalkyloxyalkyl or R.sup.5 together with OR.sup.4 represents O(CH.sub.2).sub.n O wherein n is 2, 3 or 4; and

R.sup.3 represents hydrogen, halogen, alkyl or alkoxy or R.sup.3 together with R.sup.2 represents a moiety of formula (c): ##STR3## or an ester or amide thereof; a pharmaceutical composition containing such a compound, a process of preparing such a compound and the use of such a compound in medicine.

SUMM These compounds are also indicated to have potential in the treatment of gastrointestinal disorders such as peptic ulceration, **oesophagitis**, gastritis and duodenitis, intestinal ulcerations, including inflammatory bowel disease, and irritable bowel syndrome and also for the treatment of gastrointestinal. . .

SUMM . . . salt thereof, or a pharmaceutically acceptable solvate thereof, for use in the treatment of gastrointestinal disorders such as peptic ulceration, **oesophagitis**, gastritis and duodenitis, intestinal ulcerations, including inflammatory bowel disease, and irritable bowel syndrome and also for the treatment of gastrointestinal. . .

SUMM The present invention further provides a method for treating gastrointestinal disorders such as peptic ulceration, **oesophagitis**, gastritis and duodenitis, intestinal ulcerations, including inflammatory bowel disease, and irritable bowel syndrome and also for the treatment of gastrointestinal. . .

SUMM . . . solvate thereof, for the manufacture of a medicament for the treatment of: hyperglycaemia, obesity, gastrointestinal disorders such as peptic ulceration, **oesophagitis**, gastritis and duodenitis, intestinal ulcerations, including inflammatory bowel disease, and irritable bowel syndrome and also for the treatment of gastrointestinal. . .

DETD Antagonist and Agonist Activity at Human .beta..sub.1, .beta..sub.2, and .**beta**..sub.3 -**Adrenoceptors**.

DETD Subclones of CHO cells are stably transfected with each of the human

.beta..sub.1, .beta..sub.2 and .**beta**..sub.3 - **adrenoceptors**.sup.1. Cells are then disrupted by immersion in ice-cold lysis buffer (10 mM TRIS, 2 mM EDTA, pH 7.4) containing protease. . .

DETD .**beta**..sub.3 -**Adrenoceptor**-Mediated Adenylyl Cyclase Activity

DETD . . . 40 .mu.l (70-80 .mu.g protein) to the incubation medium of the above CHO cell plasma membranes transfected with the human .**beta**..sub.3 -**adrenoceptor**. cAMP produced over 20 minutes is separated from ATP by the method of Salomon et al..sup.4. Agonist EC.sub.50 values and. . .

DETD Antagonist Binding at .beta..sub.1, and .**beta**..sub.2 - **Adrenoceptors**

DETD Displacement of [.sup.125 I]-iodocyanopindolol from CHO cell plasma membranes transfected with either the human .beta..sub.1, or .**beta**..sub.2 -**adrenoceptors** is carried out by the method of Blin et. al..sup.5. Ki values (nM) are calculated from the binding IC.sub.50 values. . .

```
=> s l1 and gastritis
L3          53 L1 AND GASTRITIS

=> s l3 and pd<1992
   4 FILES SEARCHED...
'1992' NOT A VALID FIELD CODE
  10 FILES SEARCHED...
'1992' NOT A VALID FIELD CODE
'1992' NOT A VALID FIELD CODE
  17 FILES SEARCHED...
'1992' NOT A VALID FIELD CODE
'1992' NOT A VALID FIELD CODE
  24 FILES SEARCHED...
'1992' NOT A VALID FIELD CODE
'1992' NOT A VALID FIELD CODE
'1992' NOT A VALID FIELD CODE
'1992' NOT A VALID FIELD CODE
  34 FILES SEARCHED...
  35 FILES SEARCHED...
L4           7 L3 AND PD<1992

=> d l4 1-7 bib,ab,kwic

L4   ANSWER 1 OF 7  ADISCTI COPYRIGHT (C) 2003 Adis Data Information BV on STN
AN   1991:40763  ADISCTI
DN   800084184
TI   Effects of diltiazem and metoprolol on blood pressure, adverse symptoms
     and general well-being.
     ADIS TITLE: Diltiazem vs metoprolol: therapeutic use.
     Essential hypertension
     Effects on quality of life.
AU   Dahlof C; Hedner T; Thulin T; Gustafsson S; Olsson S O; et al.
CS   Gothenburg Medical Research Centre, Gothenburg, Sweden; AB Ferrosan,
     Malmo, Sweden.
SO   European Journal of Clinical Pharmacology (May 1, 1991), Vol.
     40, pp. 453-460
DT   Study
RE   Hypertension
FS   Summary
LA   English
WC   401
PD   19910501
```

TX. . . calcium antagonist diltiazem had a comparable or slightly better therapeutic efficacy, in terms of BP reduction versus adverse effects, than **beta** sub(1)-selective **adrenoceptor** antagonist metoprolol. Increasing doses of diltiazem led to an increased response rate without deterioration in subjective well-being.'

SIDE Side Effects Table:

| Side effects (patients) | Diltiazem | Metoprolol |
|---|---|---|
| Deep vein thrombosis | 1 sup(a) | |
| Flushing | 1 sup(a) | |
| **Gastritis** and diarrhoea | | 1 sup(a) |
| Tiredness and vertigo or headache | | 2 sup(a) |

a Withdrawn.

CT. . . use; Ischaemic heart disorder therapies, therapeutic use; Metoprolol, therapeutic use; Adrenoceptor antagonists, therapeutic use; Antiarrhythmics, therapeutic use; Antimigraines, therapeutic use; **Beta** 1 **adrenoceptor** antagonists, therapeutic use; **Beta adrenoceptor** antagonists, therapeutic use; Class II antiarrhythmics, therapeutic use; Heart failure therapies, therapeutic use; Neuropsychotherapeutics, therapeutic use; Neurotransmitter antagonists, therapeutic use

L4 ANSWER 2 OF 7 ADISCTI COPYRIGHT (C) 2003 Adis Data Information BV on STN
AN 1990:25477 ADISCTI
DN 800056010
TI A comparison of diltiazem and metoprolol in hypertension.
ADIS TITLE: Diltiazem vs metoprolol: therapeutic use.
Essential hypertension
Effects on lipids.
AU Hedner T; Thulin T; Gustafsson S; Olsson S O.
CS Sahlgrenska University Hospital, Gothenburg, Sweden.
SO European Journal of Clinical Pharmacology (**Nov 1, 1990**), Vol. 39, pp. 427-433
DT Study
RE Hypertension
FS Summary
LA English
WC 300
PD **19901101**

SIDE. . . because of deep vein thrombosis (n = 1), and flushing (1). Three patients in the metoprolol group withdrew because of **gastritis** and diarrhoea (1), tiredness and vertigo (1) and tiredness and headache (1).

CT. . . use; Ischaemic heart disorder therapies, therapeutic use; Metoprolol, therapeutic use; Adrenoceptor antagonists, therapeutic use; Antiarrhythmics, therapeutic use; Antimigraines, therapeutic use; **Beta** 1 **adrenoceptor** antagonists, therapeutic use; **Beta adrenoceptor** antagonists, therapeutic use; Class II antiarrhythmics, therapeutic use; Heart failure therapies, therapeutic use; Neuropsychotherapeutics, therapeutic use; Neurotransmitter antagonists, therapeutic use

L4 ANSWER 3 OF 7 USPATFULL on STN
AN 91:62802 USPATFULL
TI Benzothiazoles
IN Young, Robert N., Senneville, Canada
Zamboni, Robert, Longueuil, Canada
PA Merck Frosst Canada, Inc., Kirkland, Canada (non-U.S. corporation)

PI US 5037840 19910806 <--
AI US 1990-489305 19900305 (7)
RLI Division of Ser. No. US 1987-125049, filed on 25 Nov 1987, now patented, Pat. No. US 4957932
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Lopez, Gabriel, DiPrima, Joseph F.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1031
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful an anti-asthmatic, antiallergic, anti-inflammatory, and cytoprotective agents.
PI US 5037840 19910806 <--
SUMM . . . of the present invention may also be used to treat or prevent mammalian (especially, human) disease states such as erosive **gastritis**; erosive esophagitis; inflammatory bowel disease; ethanol induced hemorrhagic erosions; hepatic ischemic; noxious agent induced damage or necrosis of hepatic, pancreatic,. . .
SUMM . . . bathing solution was continuously aerated with 95% O.sub.2 and 5% CO.sub.2 and bath temperature was maintained at 37.degree. C. The **beta-adrenoceptor** blocker, timolol (0.5 .mu.g/ml) and the antimuscarinic agent atropine (1.0 .mu.M) were present in the Tyrode's solution. Isometric tension changes. . .

L4 ANSWER 4 OF 7 USPATFULL on STN
AN 91:26617 USPATFULL
TI Pyridyl styrene dialkanoic acids as anti-leukotriene agents
IN Young, Robert N., Senneville, Canada
Zamboni, Robert, Longueuil, Canada
Gauthier, Jacques Y., Laval, Canada
PA Merck Frosst Canada, Inc., Kirkland, Canada (non-U.S. corporation)
PI US 5004743 19910402 <--
AI US 1987-125637 19871125 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Mary C.; Assistant Examiner: Whittenbaugh, Robert C .
LREP Lopez, Gabriel, Pfeiffer, Hesna J.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1,6
DRWN No Drawings
LN.CNT 1050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.
PI US 5004743 19910402 <--
SUMM . . . of the present invention may also be used to treat or prevent mammalian (especially, human) disease states such as erosive **gastritis**; erosive esophagitis; inflammatory bowel disease; ethanol-induced hemorrhagic erosions; hepatic ischemic; noxious agent induced damage or necrosis of hepatic, pancreatic, renal,. . .
SUMM . . . bathing solution was continuously aerated with 95% O.sub.2 and 5% CO.sub.2 and bath temperature was maintained at 37.degree. C. The **beta-adrenoceptor** blocker, timolol (0.5 .mu.g/ml) and the antimuscarinic agent atropine (1.0 .mu.M) were present in the

Tyrode's solution. Isometric tension changes. . .

L4 ANSWER 5 OF 7 USPATFULL on STN
AN 90:78336 USPATFULL
TI 2-substituted quinolines useful as leukotriene antagonists
IN Young, Robert N., Quebec, Canada
Williams, Haydn W. R., Dollard des Ormeaux, Canada
Leger, Serge, Dollard des Ormeaux, Canada
Frenette, Richard, Laval, Canada
Zamboni, Robert, Longueuil, Canada
PA Merck Frost Canada, Inc., Kirkland, Canada (non-U.S. corporation)
PI US 4962203 19901009 <--
AI US 1989-393436 19890814 (7)
RLI Continuation of Ser. No. US 1988-253993, filed on 5 Oct 1988, now abandoned which is a continuation of Ser. No. US 1986-874243, filed on 13 Jun 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-746204, filed on 18 Jun 1985, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Daus, Donald G.
LREP Lopez, Gabriel, Pfeiffer, Hesna J.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula: ##STR1## are selective antagonists of leukotrienes of D.sub.4. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.
PI US 4962203 19901009 <--
SUMM . . . of the present invention may also be used to treat or prevent mammalian (especially, human) disease states such as erosive **gastritis**; erosive esophagitis; inflammatory bowel disease; ethanol-induced hemorrhagic erosions; hepatic ischemia; noxious agent induced damage or necrosis of hepatic, pancreatic, renal,. . .
SUMM . . . bathing solution was continuously aerated with 95% O.sub.2 and 5% CO.sub.2 and bath temperature was maintained at 37.degree. C. The **beta adrenoceptor** blocker, timolol (0.5 .mu.g/mL) and the antimuscarinic agent atropine (1.0 .mu.M) were present in the Tyrode.mu.s solution. Isometric tension changes. . .

L4 ANSWER 6 OF 7 USPATFULL on STN
AN 90:78252 USPATFULL
TI Heterazole dialkanoic acids
IN Young, Robert N., Senneville, Canada
Atkinson, Joseph G., Montreal, Canada
PA Merck Frosst Canada, Inc., Kirkland, Canada (non-U.S. corporation)
PI US 4962117 19901009 <--
AI US 1988-265972 19881102 (7)
RLI Continuation-in-part of Ser. No. US 1987-125622, filed on 25 Nov 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Lopez, Gabriel, Pfeiffer, Hesna J.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as

anti-asthmatic, antiallergic, anti-inflammatory, and cytoprotective agents.

PI US 4962117 19901009 <--

SUMM . . . of the present invention may also be used to treat or prevent mammalian (especially, human) disease states such as erosive **gastritis**; erosive esophagitis; inflammatory bowel disease; ethanol-induced hemorrhagic erosions; hepatic ischemic; noxious agent induced damage or necrosis of hepatic, pancreatic, renal,. . .

SUMM . . . The bathing solution is continuously aerated with 950.sub.2 and 5% CO.sub.2 and bath temperature is maintained at 37.degree. C. The **beta-adrenoceptor** blocker, timolol (0.5 .mu.g/ml) and the antimuscarinic agent atropine (1.0 .mu.M) are present in the Tyrode's solution. Isometric tension changes. . .

L4 ANSWER 7 OF 7 USPATFULL on STN

AN 90:73497 USPATFULL

TI Benzoheterazoles

IN Young, Robert N., Senneville, Canada
Zamboni, Robert, Longueuil, Canada

PA Merck Frosst Canada, Inc., Kirkland, Canada (non-U.S. corporation)

PI US 4957932 19900918 <--

AI US 1987-125049 19871125 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Gerstl, Robert

LREP Lopez, Gabriel, Pfeiffer, Hesna J.

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1038

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having the formula: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, antiallergic, anti-inflammatory, and cytoprotective agents.

PI US 4957932 19900918 <--

SUMM . . . of the present invention may also be used to treat or prevent mammalian (especially, human) disease states such as erosive **gastritis**; erosive esophagitis; inflammatory bowel disease; ethanol-induced hemorrhagic erosions; hepatic ischemic; noxious agent induced damage or necrosis of hepatic, pancreatic, renal,. . .

DETD . . . bathing solution was continuously aerated with 95% O.sub.2 and 5% CO.sub.2 and bath temperature was maintained at 37.degree. C. The **beta-adrenoceptor** blocker, timolol (0.5 .mu.g/ml) and the antimuscarinic agent atropine (1.0 .mu.M) were present in the Tyrode's solution. Isometric tension changes. . .